Acutaas Chemicals (ACUTAAS) Q3 24/25 earnings summary

Executive summary

• Q3 FY25 revenue reached INR 275 crore (Rs. 2,750 mn), up 65.2% YoY, driven by strong CDMO ramp-up and advanced pharma intermediates growth.

• Nine-month FY25 revenue nearly matched the previous full year at INR 698 crore (Rs. 6,984 mn), with 41.8% YoY growth.

• Management revised FY25 growth guidance upward from 30% to 35% due to strong Q4 visibility.

• Unaudited standalone and consolidated financial results for Q3 and nine months ended December 31, 2024, were approved and reviewed without modifications by statutory auditors.

• Financial statements prepared in accordance with Ind AS and SEBI regulations.

Financial highlights

• Q3 FY25 gross profit was INR 127.2 crore, up 78% YoY; gross margin expanded to 46.2%.

• Q3 FY25 EBITDA was INR 68.7 crore (25% margin), up 159% YoY; PAT was INR 45.4 crore, up 155.1% YoY.

• Nine-month FY25 EBITDA was INR 146.6 crore, PAT at INR 97.7 crore, both up significantly YoY.

• Export revenue share at 76% in Q3 FY25; domestic business at 24%.

• Net cash and cash equivalents stood at INR 306 crore.

Outlook and guidance

• FY25 revenue growth guidance raised to 35% from 30%, with improved EBITDA margins expected.

• Management targets doubling revenue in three years (25%+ CAGR), with margin improvement expected over the next two years.

• CDMO business expected to reach INR 1,000 crore by FY28, up from INR 80-90 crore last year.

• CDMO segment expected to see exponential growth with several projects nearing commercialization by FY26.